Armata Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Armata Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Debt, after subtracting cash, is 2.2 times its market value (net debt). Lower than 97% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-10.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 51% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-5.6×Operating cash was negative last year, while some debt falls due within a year.
Higher than 58% of Healthcare companies in United States.
Cash Cushion Ratio
2.2× debtDebt, after subtracting cash, is 2.2 times its market value (net debt).
Lower than 97% of Healthcare companies in United States.
Tangible Assets Ratio
82%Of every $100 the company owns, $82 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 52% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Armata Pharmaceuticals, Inc. made a loss over the last year. Armata Pharmaceuticals, Inc. owes $5.46 for every $1 it owns. Armata Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossArmata Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.41Armata Pharmaceuticals, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$128 MThe total market value of all of Armata Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 63% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
NegativeArmata Pharmaceuticals, Inc.'s net worth is negative ($312 M below zero, balance sheet 31 Mar 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
5.46×Armata Pharmaceuticals, Inc. owes $5.46 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Dividend yield
NoneArmata Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossArmata Pharmaceuticals, Inc. made a loss in each of the last two years.
Interest cover
Not coveredArmata Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net debtArmata Pharmaceuticals, Inc. had $279 M more debt than cash (net debt) at Dec 2025.
Questions
How much does Armata Pharmaceuticals, Inc. owe compared with what it owns?
Armata Pharmaceuticals, Inc. owes $5.46 for every $1 it owns, so it owes more than it owns, higher than almost all Healthcare companies in United States.
Does Armata Pharmaceuticals, Inc. pay a dividend?
No. Armata Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.